{"id":"4ac767a6-8420-56f4-a758-d50065e0d38c","stable_key":"63ce713e-6aea-59f6-9896-ca30e010b2ce:l-tyrosine-nitisinone-network","predicate":"increases","statement":"During nitisinone treatment in SONIA 2, urinary derivatives upstream of homogentisate increased and tracked treatment-associated hypertyrosinemia.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"e57049b2-62b9-5e9d-90c5-4ab2f2420c41","mechanism_event_label":"Blocking one step changes the distribution of metabolites across other routes.","subject":{"id":"b994753a-69d4-5f99-805d-198ee0010616","slug":"nitisinone","display_name":"Nitisinone","entity_type_key":"drug"},"object":{"id":"7a57d928-a7c3-567f-9aae-59076c8c37f0","slug":"human-aku-alternative-tyrosine-metabolites","display_name":"Human alkaptonuria alternative urinary tyrosine metabolites","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e57049b2-62b9-5e9d-90c5-4ab2f2420c41","stable_key":"63ce713e-6aea-59f6-9896-ca30e010b2ce:l-tyrosine-nitisinone-network-event","event_type":"observed_relationship","label":"Blocking one step changes the distribution of metabolites across other routes.","description":"During nitisinone treatment in SONIA 2, urinary derivatives upstream of homogentisate increased and tracked treatment-associated hypertyrosinemia.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"b994753a-69d4-5f99-805d-198ee0010616","slug":"nitisinone","display_name":"Nitisinone","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"7a57d928-a7c3-567f-9aae-59076c8c37f0","slug":"human-aku-alternative-tyrosine-metabolites","display_name":"Human alkaptonuria alternative urinary tyrosine metabolites","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"bcfef85f-831d-5439-ba51-1aef4b090441","slug":"l-tyrosine","display_name":"L-Tyrosine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"9e57c89c-2e87-5bc7-b2b9-29b122942fdd","slug":"4-hydroxyphenylpyruvate","display_name":"4-Hydroxyphenylpyruvate","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"ea7ed42c-7c9f-5d5a-912a-7b67e60df93e","slug":"homogentisate","display_name":"Homogentisate","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"9aabe27f-74c1-5758-8ac1-0105cbddb5f1","slug":"hpd","display_name":"Human 4-hydroxyphenylpyruvate dioxygenase / HPD","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"AKU trial samples at baseline, 24 and 48 months; 47 treated serum and 53 treated urine sample series, with untreated comparisons.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Metabolite associations do not identify every conjugating enzyme or prove the proposed clearance benefit. This exposure is pharmacological.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Tyrosine collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"l-tyrosine","display_name":"L-Tyrosine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Blocking one step changes the distribution of metabolites across other routes.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria. · 2022 · https://pubmed.ncbi.nlm.nih.gov/36295829/ · DOI 10.3390/metabo12100927","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"0c189bf3-e67e-5b94-97c1-3c088a607fa9","evidence_kind":"source_excerpt","locator":"Lines 308-314","start_line":308,"end_line":314,"excerpt":"## l-tyrosine-nitisinone-network\nBlocking one step changes the distribution of metabolites across other routes.\nDuring nitisinone treatment in SONIA 2, urinary derivatives upstream of homogentisate increased and tracked treatment-associated hypertyrosinemia.\nModel: AKU trial samples at baseline, 24 and 48 months; 47 treated serum and 53 treated urine sample series, with untreated comparisons.\nLimitations: Metabolite associations do not identify every conjugating enzyme or prove the proposed clearance benefit. This exposure is pharmacological.\nEvidence access: Primary abstract\nComprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria. · 2022 · https://pubmed.ncbi.nlm.nih.gov/36295829/ · DOI 10.3390/metabo12100927","model_system":"AKU trial samples at baseline, 24 and 48 months; 47 treated serum and 53 treated urine sample series, with untreated comparisons.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"12917df2-c6e0-5b61-850f-dbff6d4b4d30","stable_key":"import-63ce713e-6aea-59f6-9896-ca30e010b2ce","title":"L-Tyrosine: catecholamines, thyroid chemistry, pigment, metabolism and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"7777f4440a8bfb14a04ff73e73392ccc45d8ee89f7853ecbcc0027d6f563b8a0","revision_id":"e1206111-3a75-5809-b8e9-231ff809ff1e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}